| Ytd | ||
| 1y |
| Open | 0.35 | Prev Close | 0.35 | Low | 0.35 | High | 0.36 | Mkt Cap | 8.21M |
| Vol | 0.00 | Avg Vol | 404.93K | EPS | -2.04 | P/E | -0.17 | Forward P/E | -0.19 |
| Beta | 1.36 | Short Ratio | 1.03 | Inst. Own | 60.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.36 | 200-d Avg | 0.41 | 1yr Est | 2.38 |
TSBX News
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”)
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company
Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing opti
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most poten
Turnstone Biologics Corp. TSBX stock is trading lower after the company released initial data from i
Turnstone Biologics (NASDAQ: TSBX ) stock is falling on Thursday following the release of the clinic
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer inclu
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four eva
Are you looking for stocks to buy with low price tags?
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”)
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”)
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company
Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”
Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sa
– Promising preclinical data showcasing Turnstone's novel Selected TIL programs for solid tumors pre
Posters showcase Turnstone's novel Selected TIL programs which are designed to selectively expand th
On Wednesday, 311 stocks hit new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.